Chimeric Antigen Receptors are a promising therapy for hematological malignancies, but challenges remain. Learn how combining nS/MARt technology with our Flow #Electroporation technology generated recombinant T cells in only 5 days. https://maxcyte.com/electroporation-of-a-non-integrative-dna-nanovector-for-efficient-semi-automated-gmp-manufacturing-of-car-t-cell-therapies-5/

When it comes to pancreatic cancer, the prognosis is grim. With the cell-engineering technology of choice, we’re empowering researchers to develop new cell-based therapies to improve patient outcomes. #WorldPancreaticCancerDay

Don’t miss MaxCyte’s fireside chat tomorrow @ 10:00 am EST. Our CEO will be chatting with @Stephens_Inc to share how we’re driving a new generation of cell-based medicines. Live and archived webcasts will be available: https://investors.maxcyte.com

A clinical trial in which scientists used #geneediting to stop the body’s ability to produce tainted hemoglobin has given Jimi Olaghere new hope. At MaxCyte, we’re proud to be part of this life-changing field. Read Jimi’s story here: https://www.bbc.com/news/health-60348497

Catch up with MaxCyte’s CEO at our fireside chat with @Stifel tomorrow @ 3 pm EST to gain insight into how we’re driving a new generation of cell-based medicines. Live and archived webcasts will be available: https://investors.maxcyte.com/